Interactions of Globular and Ribbon [γ4E]GID with α4β2 Neuronal Nicotinic Acetylcholine Receptor

Area of Science:

• Neuroscience
• Pharmacology
• Computational Chemistry

Background:

• The α4β2 nicotinic acetylcholine receptor (nAChR) is a key target in neurological diseases, including nicotine addiction, epilepsy, Parkinson's, and Alzheimer's.
• Selective inhibitors of α4β2 nAChR are needed to elucidate its role in disease and develop targeted therapies.

Purpose of the Study:

• To engineer globular and ribbon forms of α-conotoxin GID for selective targeting of the α4β2 nAChR.
• To investigate competitive inhibition at the α4(+)β2(-) and α4(+)α4(-) interfaces of the α4β2 nAChR.

Main Methods:

• Computational methods were employed to deduce the binding modes of modified α-conotoxin GID variants with various nAChR subtypes (α3β2, α4β2, α7).
• Published experimental mutagenesis data were used to validate computational predictions.
• The FoldX program was utilized to predict mutational energies for ribbon GID variants at the α4(+)α4(-) interface.

Main Results:

• The binding mode of globular [γ4E]GID at the α4β2 nAChR was consistent with experimental mutagenesis data, indicating its potential for GID variant design.
• Computational analysis suggested that globular [γ4E]GID exhibits optimal binding to α4β2 nAChR, with limited scope for further improvement via amino acid substitutions.
• Several ribbon [γ4E]GID mutants demonstrated promising properties for inhibiting the (α4)₃(β2)₂ nAChR, based on predicted mutational energies.

Conclusions:

• Modified α-conotoxin GID, particularly the globular [γ4E]GID variant, shows significant potential as a selective inhibitor for the α4β2 nAChR.
• The study provides a computational basis for designing novel GID-based therapeutics targeting α4β2 nAChR for neurological disorders.